Guideline-directed Medical Therapy May Not Be Harmful In Patients with Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

No guidelines exist on the use of guideline-directed medical therapy (GDMT) in the setting of transthyretin cardiac amyloidosis (TTR CA) and HFrEF, and its use remains controversial. There is no survival data demonstrating the effects of beta blockers in patients with TTR CA, and the efficacy of angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and angiotensin receptor-neprilysin inhibitors (ARNIs) are uncertain. This observational study describes the outcomes of patients with TTR CA and HFrEF treated with GDMT.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 367 Source Type: research